| Abstract: |
Intrathecal (IT) analgesic infusions have been used for decades to treat patients with chronic pain and are often used in patients who are either refractory to more conservative measures or are intolerant to systemic treatment side effects. Patients with cancer often suffer from refractory pain and thus IT therapy can be an effective treatment option for pain control. The treatment of cancer pain can be challenging and presents unique issues when compared to the treatment of non-cancer pain with intrathecal drug delivery systems (IDDSs). When considering an IDDS for cancer pain one must take into consideration the issues of patient survival, type of device, risk/benefit, and cost/benefit ratio. The focus of this chapter is using IDDSs for cancer pain. © Springer Nature Switzerland AG 2023. |
